Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Februar 2013

Planlagt Fastgjort Låst Flyttet Genmab
189 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #98

    Hvis man sammenholder det med hvad Paul Richardson sagde på post ASH seminaret - nemlig at mulighed for hurtig godkendelse var "very real" såfremt data var gode - og det viste man i løbet af et halvt års tid, så passer det med "primary completion date"

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #99

      Så måske er det efter dette, at man vil søge om breakthrough disignation, hvis altså det reelt er noget de overvejer !

      1 Reply Last reply
      0
      • MadsSkjernM Offline
        MadsSkjernM Offline
        MadsSkjern
        wrote on sidst redigeret af
        #100

        Hvis ikke de søger, så gør jeg 🐵

        1 Reply Last reply
        0
        • D Offline
          D Offline
          deleted-user
          wrote on sidst redigeret af
          #101

          hahaha mads. Genialt

          1 Reply Last reply
          0
          • D Offline
            D Offline
            deleted-user
            wrote on sidst redigeret af
            #102

            der er godt smæk på idag 172k nu @gen.co

            1 Reply Last reply
            0
            • R Offline
              R Offline
              Repsac
              wrote on sidst redigeret af
              #103

              Det kan da ikke bare være DDB nye kursmål der giver mængde og stigning i dag.

              1 Reply Last reply
              0
              • D Offline
                D Offline
                deleted-user
                wrote on sidst redigeret af
                #104

                der bliver handlet igennem nu

                1 Reply Last reply
                0
                • D Offline
                  D Offline
                  deleted-user
                  wrote on sidst redigeret af
                  #105

                  316K

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #106

                    http://www.bloomberg.com/news/2013-02-15/genmab-rises-as-danske-sees-fda-breakthrough-copenhagen-mover.html?cmpid=yhoo Måske allerede posted

                    1 Reply Last reply
                    0
                    • D Offline
                      D Offline
                      deleted-user
                      wrote on sidst redigeret af
                      #107

                      det er merill lynch, credit suisse på den ene side og ens og ddb på den anden side. Jeg tror det må være ATP der losser ud

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        gentogen
                        wrote on sidst redigeret af
                        #108

                        Vedr. Solsens link. Så kan Ofa måske profitere af Ibrutinib. In combination with ofatumumab (Arzerra) on patients with chronic lymphocytic leukemia / small lymphocytic leukemia / prolymphocytic leukemia1 (CLL/SLL/ PLL1) and Richter transformation, results demonstrate that the combination was well-tolerated and highly active in patients with heavily pretreated relapsed/refractory CLL/SLL. The drug is described to have a rapid onset of response, low relapse rate, and favorable safety profile.http

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gentogen
                          wrote on sidst redigeret af
                          #109

                          http://www.prohostbiotech.com/_blog/News_and_Comments/post/PHARMACYCLICS_IBRUTINIB,_THE_NEXT_RITUXAN_AND_MORE_/

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #110

                            eller det modsatte http://clinicaltrials.gov/ct2/show/NCT01578707?term=ofatumumab&phase=2&rank=11

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #111

                              In this ongoing trial patients with relapsed/refractory CLL/SLL who have received two or more prior therapies are treated with ibrutinib (420 mg) daily until disease progression, followed by concomitant ofatumumab with continued ibrutinib until progression.

                              For the CLL/SLL/PLL patients the overall response rate, as measured by IWCLL criteria and progression-free survival is 100%, with a median follow-up of 9.8 months

                              1 Reply Last reply
                              0
                              • D Offline
                                D Offline
                                deleted-user
                                wrote on sidst redigeret af
                                #112

                                Så de laver head to head med ofa i den indikation den er godkendt i. Det er svært at se fordelen i for Genmab.

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #113

                                  Ibrutinib bliver en stor spiller og også her har Janssen været vågne og villige til at betale for en god aftale. Lad os håbe at Daratumumab bliver en lige så stor succes - og ikke helt uvæsentligt, at Janssen sidder på både Ibrutinib og Daratumumab. Hvem ved det kan blive fremtidens killer-kombi uden kemo !

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #114

                                    Jan har tidligere nævnt, at de håbede på at GSK/Janssen ville starte fase III kombi med Ibrutinib og Ofatumumab i 2013. Det må vi se om sker !!

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #115

                                      Det tegner i hvert fald lovende for patienter, at man i fremtiden har nogle ekstremt lovende kombinationsbehandlinger uden kemo 🙂

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #116

                                        http://ir.pharmacyclics.com//ReleaseDetail.cfm?ReleaseID=739863

                                        1 Reply Last reply
                                        0
                                        • investor1989I Offline
                                          investor1989I Offline
                                          investor1989
                                          wrote on sidst redigeret af
                                          #117

                                          Det er altså meget spændende at de gør dette med ibrutinib

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger